Organon to Acquire Dermavant for Up to $1.2 Billion with $175 Million Upfront

Sep 18, 2024, 01:15 PM

Organon has announced its acquisition of Dermavant Sciences, a subsidiary of Roivant Sciences, in a deal valued at up to $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The terms of the deal involve an upfront payment of $175 million, with additional payments contingent on regulatory approval and sales milestones, potentially reaching a total of $1.2 billion. This includes $75 million on approval in AtD. Roivant's stock rose by 2.2% pre-market following the announcement. This strategic move is seen as positive for Roivant, while analysts have mixed opinions on its impact on Organon.